Zhejiang Huahai Pharmaceutical's Subsidiary Passes U.S. FDA Inspection

Stock News11-06

Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SH) announced that its subsidiary, Zhejiang Huahai Pharmaceutical Technology Co., Ltd. ("Huahai Technology"), underwent an on-site inspection by the U.S. FDA from August 18 to August 22, 2025. The inspection covered the facility's overall quality management system and oral solid dosage products. The company recently received the inspection report, confirming that Huahai Technology's production site complies with U.S. CGMP (Current Good Manufacturing Practice) requirements and has successfully passed the inspection.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1150329229?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 17:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150329229","market":"sg","top_or_hot":-1,"title":"Zhejiang Huahai Pharmaceutical's Subsidiary Passes U.S. FDA Inspection","media":"Stock News","content":"<p>Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SH) announced that its subsidiary, Zhejiang Huahai Pharmaceutical Technology Co., Ltd. (\"Huahai Technology\"), underwent an on-site inspection by the U.S. FDA from August 18 to August 22, 2025. The inspection covered the facility's overall quality management system and oral solid dosage products. The company recently received the inspection report, confirming that Huahai Technology's production site complies with U.S. CGMP (Current Good Manufacturing Practice) requirements and has successfully passed the inspection.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhejiang Huahai Pharmaceutical's Subsidiary Passes U.S. FDA Inspection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhejiang Huahai Pharmaceutical's Subsidiary Passes U.S. FDA Inspection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-06 17:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SH) announced that its subsidiary, Zhejiang Huahai Pharmaceutical Technology Co., Ltd. (\"Huahai Technology\"), underwent an on-site inspection by the U.S. FDA from August 18 to August 22, 2025. The inspection covered the facility's overall quality management system and oral solid dosage products. The company recently received the inspection report, confirming that Huahai Technology's production site complies with U.S. CGMP (Current Good Manufacturing Practice) requirements and has successfully passed the inspection.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"","article_id":"1150329229","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150329229","pubTimestamp":1762420822,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SH) announced that its subsidiary, Zhejiang Huahai Pharmaceutical Technology Co., Ltd. (\"Huahai Technology\"), underwent an on-site inspection by the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600521":"华海药业","BK0028":"国家队","BK0239":"医药制造","BK0185":"二线龙头","BK0201":"可转债","BK0188":"融资融券","BK0070":"员工持股","BK0012":"证金概念"},"translate_title":"浙江华海药业子公司通过美国FDA检查","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600521":1},"content_text":"Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SH) announced that its subsidiary, Zhejiang Huahai Pharmaceutical Technology Co., Ltd. (\"Huahai Technology\"), underwent an on-site inspection by the U.S. FDA from August 18 to August 22, 2025. The inspection covered the facility's overall quality management system and oral solid dosage products. The company recently received the inspection report, confirming that Huahai Technology's production site complies with U.S. CGMP (Current Good Manufacturing Practice) requirements and has successfully passed the inspection.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1150329229","isCrawlerRequest":true}